News | Antiplatelet and Anticoagulation Therapies | September 01, 2021

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 

Hot Line session at ESC Congress does not support the use of one month DAPT

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing stent implantation. That was the finding of late-breaking research presented in a Hot Line session at European Society of Cardiology (ESC) Congress 2021.[1]

“One-month DAPT and subsequent clopidogrel monotherapy failed to achieve noninferiority for net clinical benefit compared with standard 12-month DAPT after ACS. There was a trend toward an increase in cardiovascular events despite a reduction in major bleeding events," explained study author Dr. Hirotoshi Watanabe of Kyoto University, Japan.

The STOPDAPT-2 trial previously demonstrated that among patients undergoing percutaneous coronary intervention (PCI), one month of DAPT followed by clopidogrel monotherapy resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, compared with 12 months of DAPT with aspirin and clopidogrel.[2] In that trial, 62% of patients had stable coronary artery disease and 38% had ACS.

To generate sufficient statistical power to compare the effect of the two treatments in ACS patients alone, the STOPDAPT-2 ACS trial enrolled 2,988 ACS patients and pooled the results with the 1,148 ACS patients in STOPDAPT-2 – for a total of 4,136 patients. Both trials used the same protocol. Participants were randomly assigned in a 1:1 ratio to one-month DAPT followed by clopidogrel monotherapy or 12-month DAPT after PCI with cobalt-chromium everolimus-eluting stents.

The primary outcome was a composite of cardiovascular and bleeding outcomes at one year: death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke, and Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding.

The two major secondary endpoints were: 1) a cardiovascular composite outcome (death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke); and 2) TIMI major or minor bleeding.

The primary outcome occurred in 65 patients (3.2% one-year cumulative incidence) assigned to one-month DAPT and 58 patients (2.83%) assigned to 12-month DAPT (hazard ratio [HR] 1.14; 95% confidence interval [CI] 0.80–1.62; p=0.06 for noninferiority).

The major secondary cardiovascular outcome occurred in 56 (2.76%) patients in the one-month DAPT group and 38 (1.86%) patients in the 12-month DAPT group (HR 1.5; 95% CI 0.99–2.26). The major secondary bleeding outcome occurred in 11 (0.54%) patients allocated to one-month DAPT and 24 (1.17%) patients allocated to 12-month DAPT (HR 0.46; 95% CI 0.23-0.94). 

Find more ESC Hot Line late-breaking study news

 

References:

1. STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome. https://www.clinicaltrials.gov/ct2/show/NCT03462498

2. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321:2414–2427.
 


Related Content

News | ESC

April 10, 2024 — A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular ...

Home April 10, 2024
Home
News | ESC

April 10, 2024 — An international consensus statement on how to treat atrial fibrillation with catheter or surgical ...

Home April 10, 2024
Home
News | ESC

August 22, 2023 — Heart attack patients who do not take daily aspirin have an elevated likelihood of recurrent ...

Home August 22, 2023
Home
News | ESC

August 22, 2023 — A study in more than 15,000 people has found that physical fitness is linked with a lower likelihood ...

Home August 22, 2023
Home
News | ESC

August 22, 2023 — Recognizing and acting on heart attack symptoms is linked with faster life-saving treatment, according ...

Home August 22, 2023
Home
News | ESC

March 23, 2023 — Newly-published research has debunked the idea that there is an “obesity paradox,” whereby patients ...

Home March 23, 2023
Home
News | ESC

March 17, 2023 — Discover what’s new and on the horizon in the prevention and treatment of heart rhythm disorders at ...

Home March 17, 2023
Home
News | ESC

March 10, 2023 — The first evidence that exceeding the World Health Organization (WHO) ozone limit is associated with ...

Home March 11, 2023
Home
News | ESC

September 1, 2022 — “At ESC Congress in Barcelona, we discussed the newest science in the light of our collective ...

Home September 01, 2022
Home
News | ESC

August 30, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest ...

Home August 30, 2022
Home
Subscribe Now